Abstract
Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.
Original language | English |
---|---|
Pages (from-to) | 251-257 |
Number of pages | 7 |
Journal | Cardiovascular Drugs and Therapy |
Volume | 16 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2002 |
Keywords
- HMG-CoA reductase inhibitors
- NK-140
- Novel statins
- Pitavastatin
- Pleiotropic effects
- Rosuvastatin
- ZD 4522
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
- Pharmacology